HK1098961A1 - Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnk - Google Patents
Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnkInfo
- Publication number
- HK1098961A1 HK1098961A1 HK07106404.0A HK07106404A HK1098961A1 HK 1098961 A1 HK1098961 A1 HK 1098961A1 HK 07106404 A HK07106404 A HK 07106404A HK 1098961 A1 HK1098961 A1 HK 1098961A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- jnk
- cell
- signal transduction
- transduction pathway
- peptide inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/165,250 US20030108539A1 (en) | 2000-02-14 | 2002-06-07 | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1098961A1 true HK1098961A1 (en) | 2007-08-03 |
Family
ID=29732060
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07106404.0A HK1098961A1 (en) | 2002-06-07 | 2007-06-14 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnk |
HK08106344.2A HK1111635A1 (en) | 2002-06-07 | 2008-06-07 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnk |
HK15108602.6A HK1207971A1 (en) | 2002-06-07 | 2015-09-02 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnk |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08106344.2A HK1111635A1 (en) | 2002-06-07 | 2008-06-07 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnk |
HK15108602.6A HK1207971A1 (en) | 2002-06-07 | 2015-09-02 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnk |
Country Status (14)
Country | Link |
---|---|
US (1) | US20030108539A1 (es) |
EP (7) | EP1776958B9 (es) |
JP (2) | JP4460445B2 (es) |
AT (2) | ATE372125T1 (es) |
AU (1) | AU2003274820B2 (es) |
CA (1) | CA2488695C (es) |
CY (3) | CY1108847T1 (es) |
DE (2) | DE60325429D1 (es) |
DK (2) | DK1911458T5 (es) |
ES (3) | ES2319454T3 (es) |
HK (3) | HK1098961A1 (es) |
PT (3) | PT2060265E (es) |
SI (1) | SI1776958T1 (es) |
WO (1) | WO2003103698A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8183339B1 (en) | 1999-10-12 | 2012-05-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
US20040082509A1 (en) * | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
EP1656951A1 (en) * | 2004-11-12 | 2006-05-17 | Xigen S.A. | Conjugates with enhanced cell uptake activity |
EP1661912A1 (en) * | 2004-11-29 | 2006-05-31 | Xigen S.A. | Fusion protein comprising a BH3-domain of a BH3-only protein |
US20060223807A1 (en) | 2005-03-29 | 2006-10-05 | University Of Massachusetts Medical School, A Massachusetts Corporation | Therapeutic methods for type I diabetes |
US8080517B2 (en) * | 2005-09-12 | 2011-12-20 | Xigen Sa | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
WO2007031098A1 (en) * | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
CA2663545A1 (en) | 2006-09-19 | 2008-03-27 | Phylogica Limited | Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof |
JP2010516707A (ja) * | 2007-01-19 | 2010-05-20 | カイ ファーマシューティカルズ インコーポレーティッド | ペプチド組成物の安定性および送達効率を上昇させるための修飾方法 |
US8822409B2 (en) | 2007-06-20 | 2014-09-02 | Phylogica Limited | Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith |
WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2009143864A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
KR20120022721A (ko) * | 2009-03-30 | 2012-03-12 | 산텐 세이야꾸 가부시키가이샤 | JNK(c-Jun 아미노 말단 키나제) 저해 펩티드를 이용한 망막 질환의 예방 또는 치료제, 망막 질환의 예방 또는 치료 방법, 및 이 펩티드의 용도 |
JP5457813B2 (ja) * | 2009-12-16 | 2014-04-02 | ルネサスエレクトロニクス株式会社 | Adpll回路、半導体装置及び携帯情報機器 |
WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
US9150618B2 (en) | 2010-10-14 | 2015-10-06 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
WO2012112810A1 (en) * | 2011-02-18 | 2012-08-23 | Otonomy, Inc. | Prevention of and recovery from drug-induced ototoxicity |
EA201491062A1 (ru) * | 2011-11-30 | 2014-10-30 | Ксиджен Инфлэммэйшн Лтд. | Применение обладающих способностью проникать в клетку пептидных ингибиторов пути трансдукции сигнала jnk для лечения синдрома сухости глаз |
WO2013091670A1 (en) | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
US10624948B2 (en) | 2013-06-26 | 2020-04-21 | Xigen Inflammation Ltd. | Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases |
WO2014206426A1 (en) * | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
GB201719520D0 (en) * | 2017-11-24 | 2018-01-10 | Univ College Cardiff Consultants Ltd | Neuroprotectvie peptide |
CN109182250A (zh) * | 2018-09-30 | 2019-01-11 | 山东省立医院 | 一种小鼠耳蜗毛细胞培养方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US817457A (en) * | 1906-01-18 | 1906-04-10 | Kelley M Turner | Head band or support for telephone-receivers. |
US1447969A (en) * | 1922-05-12 | 1923-03-13 | Brandes Inc C | Telephone head set |
US4048453A (en) * | 1976-02-11 | 1977-09-13 | Gustave Seidel | Telephone handset support device |
US4631211A (en) * | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5747641A (en) * | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
DE4005783A1 (de) * | 1990-02-23 | 1991-09-05 | Andreas Suckert | Kopfhalterung fuer telefonhoerer |
EP0656950B1 (en) * | 1992-08-21 | 1998-11-04 | Biogen, Inc. | Tat-derived transport polypeptides |
AU689758B2 (en) | 1992-10-09 | 1998-04-09 | Advanced Tissue Sciences, Inc. | Liver reserve cells |
JPH10508205A (ja) * | 1995-04-25 | 1998-08-18 | バクスター インターナショナル インコーポレイテッド | 肝細胞および膵臓ランゲルハンス島細胞を単離するためのコラーゲナーゼおよびキモパパインを含有する組成物 |
CN1208438A (zh) | 1995-07-28 | 1999-02-17 | 玛丽·柯里癌症治疗中心 | 转运蛋白及其应用 |
US5689558A (en) * | 1996-03-25 | 1997-11-18 | Osgood; Alan G. | Telephone handset holder |
US5880261A (en) * | 1997-04-03 | 1999-03-09 | Waeber; Gerard | Transcription factor Islet-Brain 1 (IB1) |
US5828749A (en) * | 1997-04-04 | 1998-10-27 | Brodskiy; Arkadiy | Phone holder kit |
US6043083A (en) * | 1997-04-28 | 2000-03-28 | Davis; Roger J. | Inhibitors of the JNK signal transduction pathway and methods of use |
EP0897002A3 (en) * | 1997-08-14 | 2001-10-04 | Smithkline Beecham Plc | U62317, a protein having a JNK-binding domain |
EP0947524A1 (en) * | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
AU3714499A (en) * | 1998-05-14 | 1999-11-29 | Pasteur Merieux Serums Et Vaccins | Hepatitis c virus mimotopes |
US6348185B1 (en) * | 1998-06-20 | 2002-02-19 | Washington University School Of Medicine | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
EP1126855B1 (en) * | 1998-09-25 | 2007-05-09 | Cephalon, Inc. | Use of fused pyrrolocarbazoles for preventing/treating damage to sensory hair cells and cochlear neurons |
US6610820B1 (en) * | 1999-10-12 | 2003-08-26 | University Of Lausanne | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
IL149933A0 (en) * | 1999-12-06 | 2002-11-10 | Gen Hospital Corp | Pancreatic stem cells and their use in transplantation |
AU1112202A (en) * | 2000-10-17 | 2002-04-29 | Diatranz Ltd | Preparation and xenotransplantation or porcine islets |
EP1373308B1 (en) * | 2001-04-06 | 2006-10-25 | Thomas Jefferson University | Antagonist for multimerization of hiv-1 vif protein |
DE10117281A1 (de) * | 2001-04-06 | 2002-10-24 | Inst Molekulare Biotechnologie | Peptid zur Diagnose und Therapie der Alzheimer-Demenz |
-
2002
- 2002-06-07 US US10/165,250 patent/US20030108539A1/en not_active Abandoned
-
2003
- 2003-06-09 WO PCT/IB2003/003094 patent/WO2003103698A1/en active IP Right Grant
- 2003-06-09 ES ES06019172T patent/ES2319454T3/es not_active Expired - Lifetime
- 2003-06-09 EP EP06019172.3A patent/EP1776958B9/en not_active Expired - Lifetime
- 2003-06-09 SI SI200331484T patent/SI1776958T1/sl unknown
- 2003-06-09 ES ES07016361.3T patent/ES2473274T3/es not_active Expired - Lifetime
- 2003-06-09 AT AT03740977T patent/ATE372125T1/de not_active IP Right Cessation
- 2003-06-09 ES ES08021394.5T patent/ES2439950T3/es not_active Expired - Lifetime
- 2003-06-09 DE DE60325429T patent/DE60325429D1/de not_active Expired - Lifetime
- 2003-06-09 PT PT80213945T patent/PT2060265E/pt unknown
- 2003-06-09 PT PT06019172T patent/PT1776958E/pt unknown
- 2003-06-09 EP EP08021394.5A patent/EP2060265B1/en not_active Expired - Lifetime
- 2003-06-09 CA CA2488695A patent/CA2488695C/en not_active Expired - Lifetime
- 2003-06-09 DK DK07016361.3T patent/DK1911458T5/da active
- 2003-06-09 AT AT06019172T patent/ATE417623T1/de active
- 2003-06-09 PT PT70163613T patent/PT1911458E/pt unknown
- 2003-06-09 JP JP2004510817A patent/JP4460445B2/ja not_active Expired - Lifetime
- 2003-06-09 DK DK06019172.3T patent/DK1776958T5/da active
- 2003-06-09 EP EP12001707.4A patent/EP2532357A3/en not_active Withdrawn
- 2003-06-09 AU AU2003274820A patent/AU2003274820B2/en not_active Ceased
- 2003-06-09 DE DE60316149T patent/DE60316149D1/de not_active Expired - Lifetime
- 2003-06-09 EP EP03740977A patent/EP1511507B1/en not_active Expired - Lifetime
- 2003-06-09 EP EP14001780.7A patent/EP2845603A1/en not_active Withdrawn
- 2003-06-09 EP EP07016361.3A patent/EP1911458B9/en not_active Expired - Lifetime
- 2003-06-09 EP EP07023486A patent/EP1970070A3/en not_active Ceased
-
2007
- 2007-06-14 HK HK07106404.0A patent/HK1098961A1/xx not_active IP Right Cessation
-
2008
- 2008-06-07 HK HK08106344.2A patent/HK1111635A1/xx not_active IP Right Cessation
-
2009
- 2009-03-05 CY CY20091100251T patent/CY1108847T1/el unknown
- 2009-11-30 JP JP2009272904A patent/JP2010053136A/ja not_active Withdrawn
-
2013
- 2013-12-11 CY CY20131101120T patent/CY1114715T1/el unknown
-
2014
- 2014-04-15 CY CY20141100286T patent/CY1115331T1/el unknown
-
2015
- 2015-09-02 HK HK15108602.6A patent/HK1207971A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1207971A1 (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnk | |
HK1100958A1 (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway jnk | |
HK1223948A1 (zh) | 信號轉導途徑的細胞可通透肽抑制劑 | |
NO20005637D0 (no) | Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav | |
WO2003057725A3 (en) | Cell-permeable peptide inhibitors of the jnk signal transduction pathway | |
IL150944A0 (en) | Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AM | Amended specification (according sect 146 of patent law) |
Free format text: XIGEN S.A. JNK Effective date: 20150630 |
|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190613 |